NCT07174570 2026-01-28Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver CancerEmory UniversityPhase 2 Recruiting39 enrolled
NCT05327738 2022-12-14Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaOHSU Knight Cancer InstitutePhase 2 Withdrawn
NCT00471484 2011-06-22Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by SurgeryNational Cancer Institute (NCI)Phase 2 Unknown54 enrolled